Evive Biotech

Evive Biotech, based in Shanghai and part of Yifan Pharmaceutical, developed efbemalenograstim alfa, sold as Ryzneuta, a long-acting G-CSF fusion protein for chemotherapy-induced neutropenia approved in the United States in 2023 and the European Union in 2024. Efbemalenograstim alfa is a dimeric G-CSF-Fc fusion protein approved by the FDA in November 2023 and by the European Commission in March 2024 to reduce the duration of neutropenia and febrile neutropenia after myelosuppressive chemotherapy. OnCo links it to the efbemalenograstim alfa drug record. Whether a new long-acting G-CSF can take share from existing long-acting G-CSFs on price or convenience is the open question. Efbemalenograstim alfa has its own page.